Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas

NCT02395601 is registered in ClinicalTrials.gov with Constellation Pharmaceuticals as lead sponsor.

NCT NCT02395601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02395601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
Lead sponsor
Constellation Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
December 31, 2018
Enrollment
41 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma